Key result
Left atrial appendage occlusion using the ACP or Amulet with aspirin monotherapy resulted in a 1.9% rate of device-related thrombosis and a 61% reduction in stroke risk compared to predicted rates.
Why the study?
Does left atrial appendage occlusion with aspirin monotherapy post-implantation prevent device-related thrombosis and stroke in patients with atrial fibrillation and high bleeding risk?
Cohort (n=107)
No
Does left atrial appendage occlusion with aspirin monotherapy post-implantation prevent device-related thrombosis and stroke in patients with atrial fibrillation and high bleeding risk?
LAAO with the ACP or Amulet followed by aspirin monotherapy appears safe and effective in high bleeding risk AF patients, with low rates of device-related thrombosis and stroke.
No takes yet. Share an insight, caveat, or question.
May support aspirin monotherapy post-LAAO in high-bleeding-risk AF; leaves open randomized confirmation of benefit.
Korsholm et al. (2017) conducted a cohort in Atrial fibrillation with high bleeding risk (n=107). Left atrial appendage occlusion (LAAO) with AMPLATZER Cardiac Plug (ACP) or Amulet plus aspirin alone was evaluated on Device-related thrombosis. Left atrial appendage occlusion using the ACP or Amulet with aspirin monotherapy resulted in a 1.9% rate of device-related thrombosis and a 61% reduction in stroke risk compared to predicted rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: